Stay updated on Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.

Latest updates to the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a new revision entry, v3.3.3, to the Record History. The HHS Vulnerability Disclosure and the previous revision entry (v3.3.2) were removed from the page footer/history.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedFooter updates include adding an HHS Vulnerability Disclosure link and updating the Revision from v3.3.1 to v3.3.2; these changes do not modify trial data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedAdded a new revision entry 'Revision: v3.3.1' to the history and removed the 'HHS Vulnerability Disclosure' item; the previous 'Revision: v3.2.0' entry remains in the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check49 days agoChange DetectedThe notice about government funding and NIH operating status in the page footer/banner was removed. This appears to be a cosmetic update with no impact on the study record or its data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedA new version entry was added to the Record History for NCT04878432, showing an updated Study Status. This reflects a recent change in the trial's status recorded by ClinicalTrials.gov.SummaryDifference0.1%

- Check78 days agoChange DetectedUpdates date-related references: adds 2025-10-16 and a '23 2025-10-08 Study Status References' entry, and removes 2025-07-31.SummaryDifference1%

Stay in the know with updates to Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.